Registry of Lobbyists
| Corporation: | Boehringer Ingelheim Canada Ltd. |
| Associated registration: | 952146-371995-2 |
| Communication date: | 2022-12-06 |
| Posted date: | 2023-01-13 |
| Designated Public Office Holders who participated in the communication: |
Daniel MacDonald,
Director General, Drugs for Rare Diseases
Health Canada (HC) Michelle Boudreau, Executive Director, Office of Pharmaceutical Management Strategies Health Canada (HC) Michelle Mujoomdar, Director, Specialty Pharmaceuticals Health Canada (HC) |
| Subject Matter of the communication: | Health |
| Responsible Officer who filed this communication report: | Andrea Sambati |
| As the most senior paid officer, the person named above is responsible for certifying the communication report for the corporation or organization (Registrant). This person may or may not have participated in the reported communication. The Lobbyists Registration Regulations do not require that the names of in-house lobbyists (i.e. employees of corporations or organizations) who actually participated in the communication be disclosed. | |